Chloroquine as a Modulator of T Cell Immune Activation

Inclusion Criteria: * Documented HIV infection by Western Blot, EIA assays or viral load assay. * Aged between 18 and 65 years. * Viral load less than 50 copies per ml for at least the previous 36 weeks. * CD4 cell count less than or equal to 350 cells per litre. * On stable ART * Vital signs, physical examination and laboratory results do not exhibit evidence diseases such as advanced cirrhosis or advanced liver * Karnofsky performance status greater than or equal to 80 per cent. * Participant does not require and agrees not to take, for the duration of the study, any medication that is contraindicated with chloroquine. * Able to give informed consent. Exclusion Criteria: * Active AIDS events in the last 3 months * Co-infection with active hepatitis B or C virus. * Current use or use within four weeks prior to the baseline visit, of cytotoxic agents, systemic corticosteroids or any immuno-modulatory agents. * Current use within four weeks prior to the chloroquine therapy the following medications: methadone, chlorpromazine, cimetidine, cyclosporin, methotrexate and penicillanime. * Psychiatric or cognitive disturbance or illness that could preclude compliance with the study. * Patient with clinically significant hemophilia and Von-Willebrand disease and any severe bleeding disorder. * Experimental HIV immune based therapy within 6 months of screening visit. * Allergic reaction to chloroquine. * A history of retinitis or any retinal problem. * Subjects with G6PD deficiency, porphyria, psoriasis, cirrhosis, hearing deficiency (including tinnitus), myopathy and cardiomyopathy. * Pregnant and breast-feeding women.